ATE258432T1 - Geschmacksmaskierte flüssige suspensionen - Google Patents

Geschmacksmaskierte flüssige suspensionen

Info

Publication number
ATE258432T1
ATE258432T1 AT97917939T AT97917939T ATE258432T1 AT E258432 T1 ATE258432 T1 AT E258432T1 AT 97917939 T AT97917939 T AT 97917939T AT 97917939 T AT97917939 T AT 97917939T AT E258432 T1 ATE258432 T1 AT E258432T1
Authority
AT
Austria
Prior art keywords
polymer
active ingredient
pharmaceutically active
taste
masked
Prior art date
Application number
AT97917939T
Other languages
German (de)
English (en)
Inventor
Angelo Mario Morella
Ian Hamilton Pitman
Grant Heinicke
Original Assignee
Faulding F H & Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Faulding F H & Co Ltd filed Critical Faulding F H & Co Ltd
Application granted granted Critical
Publication of ATE258432T1 publication Critical patent/ATE258432T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT97917939T 1996-05-07 1997-05-07 Geschmacksmaskierte flüssige suspensionen ATE258432T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPN9697A AUPN969796A0 (en) 1996-05-07 1996-05-07 Taste masked liquid suspensions
PCT/AU1997/000279 WO1997041839A1 (en) 1996-05-07 1997-05-07 Taste masked liquid suspensions

Publications (1)

Publication Number Publication Date
ATE258432T1 true ATE258432T1 (de) 2004-02-15

Family

ID=3794010

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97917939T ATE258432T1 (de) 1996-05-07 1997-05-07 Geschmacksmaskierte flüssige suspensionen

Country Status (11)

Country Link
US (1) US6197348B1 (cg-RX-API-DMAC10.html)
EP (1) EP0921789B1 (cg-RX-API-DMAC10.html)
JP (1) JP4624498B2 (cg-RX-API-DMAC10.html)
AT (1) ATE258432T1 (cg-RX-API-DMAC10.html)
AU (1) AUPN969796A0 (cg-RX-API-DMAC10.html)
CA (1) CA2253811C (cg-RX-API-DMAC10.html)
DE (1) DE69727386T2 (cg-RX-API-DMAC10.html)
DK (1) DK0921789T3 (cg-RX-API-DMAC10.html)
ES (1) ES2215223T3 (cg-RX-API-DMAC10.html)
PT (1) PT921789E (cg-RX-API-DMAC10.html)
WO (1) WO1997041839A1 (cg-RX-API-DMAC10.html)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2754177B1 (fr) * 1996-10-07 1999-08-06 Sanofi Sa Microspheres pharmaceutiques d'acide valproique pour administration orale
DE19809719A1 (de) 1998-03-06 1999-09-09 Roehm Gmbh Wäßrige Dispersion geeignet zur Herstellung von Überzugs- und Bindemitteln für feste orale Arzneiformen
DE19845358A1 (de) * 1998-10-02 2000-04-06 Roehm Gmbh Überzogene Arzneiformen mit kontrollierter Wirkstoffabgabe
ATE424191T1 (de) * 1999-02-04 2009-03-15 Abbott Lab Ph-unabhängige pharmazeutische formulierungen mit verlängerter freisetzung
EP1064938A1 (en) * 1999-06-28 2001-01-03 Sanofi-Synthelabo Pharmaceutical dosage forms for controlled release producing at least a timed pulse
HK1049622A1 (en) * 1999-12-28 2003-05-23 Ajinomoto Co., Inc. Oral preparations for diabetes
CA2401571A1 (en) * 2000-02-29 2001-09-07 Ilya Avrutov Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same
FR2826274B1 (fr) * 2001-06-21 2003-09-26 Aventis Pharma Sa Formulation pharmaceutique au gout masque et son procede de preparation
WO2003063822A2 (en) 2002-02-01 2003-08-07 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
BR0308343A (pt) * 2002-03-12 2006-06-06 Bristol Myers Squibb Co composições farmacêuticas na forma de pó, método para preparar uma suspensão oral de uma droga, método para mascarar o sabor amargo ou outro sabor de uma droga e suspensão oral de des-quinolona
US6930119B2 (en) * 2002-07-17 2005-08-16 Reliant Pharmaceuticals, Inc. Liquid pharmaceutical composition
WO2004026283A1 (en) * 2002-09-20 2004-04-01 Alpharma, Inc. Sequestering subunit and related compositions and metohds
US20040091544A1 (en) * 2002-11-08 2004-05-13 Ruff Michael D. Coated dibasic calcium phosphate
US20040170686A1 (en) * 2003-01-31 2004-09-02 Fredrickson Jennifer K. Suspension vehicle for coated drug particles
US20040186180A1 (en) 2003-03-21 2004-09-23 Gelotte Cathy K. Non-steroidal anti-inflammatory drug dosing regimen
US20040191326A1 (en) * 2003-03-31 2004-09-30 Reo Joseph P. Taste-masking vehicle for coated oxazolidinone particles
US7520489B2 (en) * 2003-06-17 2009-04-21 Filtertek Inc. Fluid handling device and method of making same
CL2004001884A1 (es) * 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
US20050137262A1 (en) * 2003-12-22 2005-06-23 Hu Patrick C. Highly concentrated pourable aqueous solutions of potassium ibuprofen, their preparation and their uses
EP1763337A2 (en) * 2003-12-31 2007-03-21 Actavis Group HF Immediate, controlled and sustained release formulations of galanthamine
JP2007517050A (ja) * 2003-12-31 2007-06-28 アクタビス グループ フルータフェーラグ アトモキセチン製剤
US20050163842A1 (en) * 2003-12-31 2005-07-28 Garth Boehm Rosiglitazone and metformin formulations
CA2552114A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Solid dosage formulations of galantamine
US20050163837A1 (en) * 2003-12-31 2005-07-28 Garth Boehm Rosiglitazone formulations
US20050232990A1 (en) * 2003-12-31 2005-10-20 Garth Boehm Donepezil formulations
US20050163843A1 (en) * 2003-12-31 2005-07-28 Garth Boehm Alprazolam formulations
WO2005065660A2 (en) * 2003-12-31 2005-07-21 Alpharma, Inc. Ziprasidone formulations
AU2005278894A1 (en) * 2004-08-31 2006-03-09 Pfizer Products Inc. Pharmaceutical dosage forms comprising a low-solubility drug and a polymer
GB2419094A (en) * 2004-10-12 2006-04-19 Sandoz Ag Pharmaceutical composition of unpleasnt tasing active substances
US7378109B2 (en) * 2004-12-23 2008-05-27 Council Of Scientific And Industrial Research Pharmaceutical composition for improving palatability of drugs and process for preparation thereof
CA2598668A1 (en) * 2005-02-25 2006-09-08 Mutual Pharmaceutical Company, Inc. Dosage forms of antibiotics and combinations of antibiotics and symptomatic relief agents
BRPI0611272A2 (pt) * 2005-05-03 2011-11-16 Mutual Pharmaceutical Co formulações de quinina
CN1883456B (zh) * 2005-06-20 2010-12-15 常州市第四制药厂有限公司 掩味药物颗粒及其制备方法和用途
JP2007031407A (ja) * 2005-07-29 2007-02-08 Shin Etsu Chem Co Ltd 低置換度セルロースエーテル含有コーティング用組成物及び不快な味が隠蔽されたフィルムコーティング製剤
US20070087056A1 (en) * 2005-08-09 2007-04-19 Claudia Guthmann Pharmaceutical form with sustained pH-independent active ingredient release for active ingredients having strong pH-dependent solubility
US9101160B2 (en) 2005-11-23 2015-08-11 The Coca-Cola Company Condiments with high-potency sweetener
AU2007227614B2 (en) * 2006-03-16 2011-01-06 Gsk Consumer Healthcare Sarl Solid dosage form containing a taste masked active agent
JP4892264B2 (ja) * 2006-03-30 2012-03-07 高田製薬株式会社 リスペリドン水性液剤
KR20140079441A (ko) * 2006-06-19 2014-06-26 알파마 파머슈티컬스 엘엘씨 약제학적 조성물
US7915247B1 (en) 2006-08-21 2011-03-29 Mutual Pharmaceutical Company, Inc. Methods of use of fenofibric acid
CA2665726C (en) * 2006-10-11 2016-04-19 Alpharma, Inc. Pharmaceutical compositions
US8017168B2 (en) 2006-11-02 2011-09-13 The Coca-Cola Company High-potency sweetener composition with rubisco protein, rubiscolin, rubiscolin derivatives, ace inhibitory peptides, and combinations thereof, and compositions sweetened therewith
US20100062073A1 (en) * 2006-11-29 2010-03-11 Ronald Arthur Beyerinck Pharmaceutical compositions comprising nanoparticles comprising enteric polymers casein
WO2008081774A1 (ja) * 2006-12-26 2008-07-10 Shionogi & Co., Ltd. リスペリドンを含有する口腔内崩壊錠剤および苦味抑制製剤
JP4941977B2 (ja) * 2007-04-11 2012-05-30 大蔵製薬株式会社 ベンズイソキサゾール誘導体の経口ゼリー状医薬組成物
WO2008125940A2 (en) * 2007-04-17 2008-10-23 Pfizer Products Inc. Nanoparticles comprising non-crystalline drug
WO2008135852A2 (en) * 2007-05-03 2008-11-13 Pfizer Products Inc. Pharmaceutical compositions comprising nanoparticles and casein
US8309129B2 (en) * 2007-05-03 2012-11-13 Bend Research, Inc. Nanoparticles comprising a drug, ethylcellulose, and a bile salt
WO2008135855A2 (en) * 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and a nonionizable polymer
US8974827B2 (en) * 2007-06-04 2015-03-10 Bend Research, Inc. Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer
US9545384B2 (en) 2007-06-04 2017-01-17 Bend Research, Inc. Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glocol succinate
EP2178518A2 (en) * 2007-07-13 2010-04-28 Bend Research, Inc Nanoparticles comprising ionizable, poorly water soluble cellulosic polymers
EP2231169B1 (en) * 2007-12-06 2016-05-04 Bend Research, Inc. Pharmaceutical compositions comprising nanoparticles and a resuspending material
EP2240162A4 (en) * 2007-12-06 2013-10-09 Bend Res Inc NANOTE PARTICLES WITH A NON-IONIZABLE POLYMER AND AN AMIN-FUNCTIONALIZED METHACRYLATE COPOLYMER
AU2008346870A1 (en) * 2007-12-17 2009-07-16 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
US8623418B2 (en) * 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
KR101294648B1 (ko) 2009-03-27 2013-08-09 도레이 카부시키가이샤 피복 고형제제
US20110150986A1 (en) * 2009-12-18 2011-06-23 Kristin Arnold Quinine formulations, method of making, and metho of use thereof
JP5819329B2 (ja) * 2010-03-09 2015-11-24 アルカーメス ファーマ アイルランド リミテッド アルコール耐性腸溶性医薬組成物
WO2013156163A1 (en) 2012-04-19 2013-10-24 Glatt Ag Taste-masked pharmaceutical compositions containing diclofenac
JP2015537029A (ja) 2012-11-14 2015-12-24 ダブリュー・アール・グレース・アンド・カンパニー−コーンＷ Ｒ Ｇｒａｃｅ ＆ Ｃｏ−Ｃｏｎｎ 生物学的に活性な物質及び不規則性無機酸化物を含有する組成物
US11202741B2 (en) * 2015-09-30 2021-12-21 Amorepacific Corporation Self-restorable core-shell capsule
US9463183B1 (en) 2015-10-30 2016-10-11 Silvergate Pharmaceuticals, Inc. Lisinopril formulations
WO2020011938A1 (en) 2018-07-11 2020-01-16 Medizinische Universität Wien Glucocorticoids for the topical treatment of autoimmune gastritis
CN113181133A (zh) * 2021-04-25 2021-07-30 海南通用三洋药业有限公司 一种罗红霉素胶囊的制备方法
CN116687843A (zh) * 2022-12-16 2023-09-05 中国人民解放军军事科学院军事医学研究院 一种高稳定性的布瓦西坦溶液及其制备方法和其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5286489A (en) * 1985-08-26 1994-02-15 The Procter & Gamble Company Taste masking compositions
JPS63150220A (ja) * 1986-12-15 1988-06-22 Dainippon Pharmaceut Co Ltd 経口用固形製剤の製造方法
JPS63218247A (ja) * 1987-03-06 1988-09-12 Yoshiaki Kawashima 高機能懸濁液
ES2054089T3 (es) * 1988-11-10 1994-08-01 Ciba Geigy Ag Formulaciones orales liquidas.
US5084278A (en) * 1989-06-02 1992-01-28 Nortec Development Associates, Inc. Taste-masked pharmaceutical compositions
IT1246383B (it) * 1990-04-17 1994-11-18 Eurand Int Metodo per il mascheramento del sapore di farmaci
AU8219191A (en) * 1990-06-14 1992-01-07 Kalmo Enterprises, Inc. Stable aqueous drug suspensions
GB9015822D0 (en) * 1990-07-18 1990-09-05 Beecham Group Plc Compositions
CA2068402C (en) * 1991-06-14 1998-09-22 Michael R. Hoy Taste mask coatings for preparation of chewable pharmaceutical tablets
DE4200821A1 (de) * 1992-01-15 1993-07-22 Bayer Ag Geschmacksmaskierte pharmazeutische mittel
JP3265680B2 (ja) * 1992-03-12 2002-03-11 大正製薬株式会社 経口製剤用組成物
CA2137265C (en) * 1992-06-04 2003-10-28 Sanjay Bhardwaj Palatable pharmaceutical compositions
WO1994025006A1 (en) 1993-04-26 1994-11-10 Affinity Biotech, Inc. Taste-masking pharmaceutical compositions and methods for making the same
ZA945944B (en) 1993-08-13 1996-02-08 Eurand America Inc Procedure for encapsulating nsaids

Also Published As

Publication number Publication date
US6197348B1 (en) 2001-03-06
JP2000509399A (ja) 2000-07-25
DK0921789T3 (da) 2004-06-01
EP0921789B1 (en) 2004-01-28
PT921789E (pt) 2004-06-30
JP4624498B2 (ja) 2011-02-02
DE69727386T2 (de) 2004-11-11
CA2253811A1 (en) 1997-11-13
ES2215223T3 (es) 2004-10-01
EP0921789A4 (en) 2002-03-13
WO1997041839A1 (en) 1997-11-13
DE69727386D1 (de) 2004-03-04
CA2253811C (en) 2006-10-24
AUPN969796A0 (en) 1996-05-30
EP0921789A1 (en) 1999-06-16

Similar Documents

Publication Publication Date Title
ATE258432T1 (de) Geschmacksmaskierte flüssige suspensionen
CA2019863A1 (en) Aqueous pharmaceutical suspension for substantially water insoluble pharmaceutical actives
CA2089430A1 (en) Aqueous pharmaceutical suspension for pharmaceutical active
DE69025208D1 (de) Arzneimittel mit verzögerter Freigabe
FI970825L (fi) Farmaseuttiset koostumukset, jotka aktiivisen yhdisteen biologisen hyötyosuuden lisäämiseksi sisältävät sappisuolaa ja puskuria
NZ295211A (en) Topical aqueous gel containing a water-soluble cellulose derivative, propylene glycol & drug(s) for haemorrhoids
WO1995009619A3 (en) Substituted urea and isothiourea derivatives as no synthase inhibitors
EP0680328A1 (en) KETOCONAZOLE COMPOSITIONS FOR LOCAL USE.
NO20040268L (no) Nye 2H-pyridazin-3-derivater, farmasoytiske preparater inneholdende slike og fremgangsmate for fremstilling av den aktive ingrediensen
FR2766368B1 (fr) Procede de preparation de nanocapsules de type vesiculaire, utilisables notamment comme vecteurs colloidaux de principes actifs pharmaceutiques ou autres
HRP20020298B1 (hr) Farmaceutske otopine levosimendana
DE69613693D1 (de) 2-heteroarylalkenylderivate der cyclopentano-heptan(heptaen)säure als therapeutisches mittel zur behandlung des erhöhten augeninnendruckes
EA199900205A1 (ru) Лекарственные формы для перорального введения, содержащие бета-лактамный антибиотик
ATE374617T1 (de) Verfahren zur herstellung eines bluddrucksenkenden mittel enthaltenden ein dipeptid als wirksames bestandteil
NO983464L (no) Buffersystemer for stabilisering av farmas°ytiske preparater
EP0717992A3 (en) Aqueous suspension formulations for pharmaceutical applications
NO307048B1 (no) N-metyl-N-[(1S)-1-fenyl-2-((3S)-3-hydroksypyrrolidin-1-yl)- etyl]-2,2-difenylacetamidhydroklorid, legemiddel som inneholder forbindelsen, anvendelse av legemidlet til fremstilling av legemiddelpreparater, farmasøytiske preparater som inneholder l
NO20022828D0 (no) Nye forgrenede substituerte aminoderivater av 3-amino-1-fenyl- 1H[1,2,4]triazol, fremgangsmåter for fremstilling av disse, ogfarmasöytiske preparater inneholdende disse
PL345309A1 (en) Benzofuran derivatives, pharmaceutical composition containing the same, and a process for the preparation of the active ingredient
NO913644D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive aminosyrederivater.
DE60029979D1 (de) LIPOSOMZUSAMMENSETZUNG VON 6,9-BIS-i(2-AMINOETHYL)-AMINOöBENZOiGöISOQUINOLIN-5,10-DIONE-DIMALEAT
NO20021527L (no) Pyrimidinderivater, fremgangsmåte for fremstilling av derivatene og legemidler inneholdende de samme som den aktivebestanddel
NO20031030D0 (no) Nye krystaller av N-hydroksy-2(S)-metyl-5-etoksymetoksy-4(S)- [N-(4-fenoksyfenylkarbonyl)amino]pentanamid, fremgangsmåte for deresfremstilling og medisinerinneholdende krystallene som den aktive bestanddel
NO962809D0 (no) Fremgangsmåte for fremstilling av N-substituerte 4-ketoprolinderivater
FR2735695B1 (fr) Compositions cosmetiques ou pharmaceutiques contenant a titre de principe actif, de la mangiferine ou ses derives

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0921789

Country of ref document: EP

EEFA Change of the company name